Electrochemical Therapy (Echt) of Cancer Tumor With an External Anode, a Way to Achieve Pathological Complete Response Publisher Pubmed



Miripour ZS^{1, 2} ; Ghahremani A¹ ; Karimi K¹ ; Jahanbakhsh F³ ; Abbasvandi F^{1, 4, 5} ; Hoseinpour P^{1, 6} ; Parniani M⁵ ; Abdolahad M^{1, 2, 7}
Source: Medical Oncology Published:2023

Abstract

There is a critical need for re-evaluation of electrochemical therapy (EChT) approaches of solid tumors to address the challenges of the currently used method: incomplete pathological response. The coexistence of anode and cathode in the tumor region resulted in acid–alkaline mixation (buffered pH) when the electrodes are so near each other (d < 1 cm), and in the non-affected lesions when the electrodes are far from each other (d > 1 cm), both have resulted in intact tumoral lesions in EChT field. Here, we presented a designation model study of EChT with an external anode out of the tumor and filled the tumor with dense distribution of cathode electrodes to completely destroy the tumoral lesions without any remaining vital tumoral residues. Anode was located in a biological ionic gel chamber (located on top of the skin) which mediates the ionic interface between the external anode and intratumoral cathode. Our newly reported method can solve the lack of a comprehensive therapeutic guideline for any solid tumors. A remarkable increase in the efficiency of EChT without any over-treating was achieved by alkaline therapy of the tumor (without any limitation in locating cathodic needles all over the tumor) and an external acidic region on top of the skin in a cylindrical gel chamber. We found that the destructive volumes and treating ability of mice tumors by this newly represented method were more significant than the conventional EChT method in fewer therapy sessions and no damage to the skin (both anode and cathode electrodes inside the tumor) (P < 0.05). Results of this study applied to mouse model tumors shed new light on returning attraction to EChT as a valuable complementary method for treating different types of solid breast tumors. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.